MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) CFO Gregory P. Hanson sold 66,550 shares of the stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $0.96, for a total transaction of $63,888.00. Following the completion of the transaction, the chief financial officer now directly owns 478,365 shares in the company, valued at approximately $459,230.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
MabVax Therapeutics Holdings, Inc. (MBVX) opened at $0.87 on Friday. The company has a market cap of $20.45, a price-to-earnings ratio of -0.25 and a beta of 1.52. MabVax Therapeutics Holdings, Inc. has a twelve month low of $0.43 and a twelve month high of $3.57. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 0.80.
MabVax Therapeutics (NASDAQ:MBVX) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.54) EPS for the quarter. equities research analysts expect that MabVax Therapeutics Holdings, Inc. will post -3.01 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3145538/gregory-p-hanson-sells-66550-shares-of-mabvax-therapeutics-holdings-inc-mbvx-stock.html.
About MabVax Therapeutics
MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.
Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.